Withdrawal of Immunomodulators After Co-treatment Does not Reduce Trough Level of Infliximab in Patients with Crohn's Disease
- Drobne, David
- Bossuyt, Peter
- Breynaert, Christine
- Cattaert, Tom
- Vande Casteele, Niels
- Compernolle, Griet
- Jürgens, Matthias
- Ferrante, Marc
- Ballet, Vera
- Wollants, Willem-Jan
- Cleynen, Isabelle
- Van Steen, Kristel
- Gils, Ann
- Rutgeerts, Paul
- Vermeire, Severine
- Van Assche, Gert
Publication date
March 2015
DOI Publisher
W.B. Saunders for the American Gastroenterological Association ISSN
1542-3565 Journal
issn:1542-7714 Citation count (estimate)
67Abstract
The addition of immunomodulators increases the efficacy of maintenance therapy with infliximab, for up to 1 year, in patients with Crohn's disease who have not been previously treated with immunomodulators. However, there are questions about the effect of withdrawing immunomodulator therapy from these patients. We studied the effects of treatment with infliximab and immunomodulators (co-treatment) and then immunomodulator withdrawal on long-term outcomes of patients, as well as trough levels of infliximab and formation of anti-infliximab antibodies (ATI).status: publishe
Add to ORKG